BeOne Medicines (ONC) Finished Goods (2017 - 2026)

BeOne Medicines (ONC) has reported Finished Goods for 5 consecutive years, with $298.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Finished Goods changed N/A year-over-year to $298.2 million; the TTM figure through Mar 2026 stood at $298.2 million (changed N/A YoY), while the FY2025 annual figure was $249.4 million, down 5.65% from the prior year.
• Finished Goods improved to $298.2 million in Q1 2026 per ONC's latest filing, from $249.4 million in the prior quarter.
• Across five years, Finished Goods topped out at $298.2 million in Q1 2026 and bottomed at $249.4 million in Q4 2025.
• Historically, Finished Goods has averaged $270.6 million across 3 years, with a median of $264.3 million in 2024.
• On a YoY basis, Finished Goods climbed as much as 5.65% in 2025 and fell as far as 5.65% in 2025.
• BeOne Medicines' Finished Goods stood at $264.3 million in 2024, then dropped by 5.65% to $249.4 million in 2025, then climbed by 19.57% to $298.2 million in 2026.
• Business Quant data shows ONC's Finished Goods at $298.2 million in Q1 2026, $249.4 million in Q4 2025, and $264.3 million in Q4 2024.